Karyopharm Therapeutics is a Newton, Massachusetts-based commercial-stage pharmaceutical company pioneering novel cancer therapies, with its lead asset XPOVIO (selinexor), an oral selective inhibitor of nuclear export (SINE) compound approved by the FDA for oncology indications including multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company is also advancing selinexor in myelofibrosis through its XPORT-MF-034 Phase 3 trial and endometrial cancer through SIENDO/XPORT-EC-042. On November 2, 2026, Karyopharm entered into a Restructuring Support Agreement and filed voluntary Chapter 11 petitions in the U.S. Bankruptcy Court for the Southern District of Texas to implement a court-supervised sale and merger with Ayrmid Ltd. as the stalking horse bidder, supported by $55 million in committed debtor-in-possession (DIP) financing to maintain ordinary operations, employee payroll, and patient drug supply uninterrupted.
Expected completion of Chapter 11 court-supervised sale/merger with Ayrmid Ltd.
Commercial-stage oncology pioneer Karyopharm Therapeutics filed voluntary Chapter 11 bankruptcy petitions in the Southern District of Texas on November 2, 2026, entering into a Restructuring Support Agreement for a planned merger with Ayrmid Ltd. as stalking-horse bidder. Karyopharm secured $55 million in committed DIP financing to maintain operations, payroll, and commercial distribution of approved nuclear export inhibitor XPOVIO (selinexor) uninterrupted during court proceedings, while existing common equity faces cancellation.
Newton-based commercial oncology biotech Karyopharm Therapeutics entered Chapter 11 bankruptcy in Texas under a Restructuring Support Agreement for a merger with stalking-horse bidder Ayrmid Ltd., securing $55M in DIP financing to keep XPOVIO commercial supply and Phase 3 trials uninterrupted.
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
With its reserves depleted, a debt payment due in four weeks and its cash runway stretching only into next month, the question for Karyopharm Therapeutics is what’s next and how soon can it happen? | With its reserves depleted, a debt payment due in four weeks and its cash runway stretching only into next month, the question for Karyopharm Therapeutics is what’s next and how soon can it happen? The company sustained a $67 million loss in the second quarter, which is greater than its current cash
Karyopharm has a month left to salvage its cancer expansion plans
President and Chief Executive Officer